Deutsche Bank
INO icon

Deutsche Bank’s Inovio Pharmaceuticals INO Stock Holding History

Deutsche Bank’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-39,025
Closed -$63.6K – 3663
2025
Q1 		$63.6K Sell
39,025
-50,839
-57% -$102K ﹤0.01% 3326
2024
Q4 		$164K Buy
89,864
+75,477
+525% +$334K ﹤0.01% 3152
2024
Q3 		$83.2K Buy
+14,387
New +$119K ﹤0.01% 3260
2023
Q2 		– Sell
-16,401
Closed -$161K – 3858
2023
Q1 		$161K Buy
16,401
+3,954
+32% +$67.4K ﹤0.01% 3107
2022
Q4 		$233K Buy
12,447
+4,434
+55% +$100K ﹤0.01% 2901
2022
Q3 		$166K Sell
8,013
-1,080
-12% -$27.6K ﹤0.01% 3052
2022
Q2 		$189K Sell
9,093
-1,184
-12% -$33.4K ﹤0.01% 3212
2022
Q1 		$443K Sell
10,277
-1,016
-9% -$45.8K ﹤0.01% 2819
2021
Q4 		$676K Buy
11,293
+563
+5% +$45.1K ﹤0.01% 2648
2021
Q3 		$922K Sell
10,730
-1,135
-10% -$114K ﹤0.01% 2673
2021
Q2 		$1.32M Sell
11,865
-238
-2% -$22.9K ﹤0.01% 2594
2021
Q1 		$1.35M Buy
12,103
+274
+2% +$36K ﹤0.01% 2471
2020
Q4 		$1.26M Buy
11,829
+3,089
+35% +$411K ﹤0.01% 2294
2020
Q3 		$1.22M Buy
8,740
+1,124
+15% +$234K ﹤0.01% 2072
2020
Q2 		$2.46M Buy
7,616
+4,778
+168% +$767K ﹤0.01% 1673
2020
Q1 		$254K Sell
2,838
-4,243
-60% -$262K ﹤0.01% 2833
2019
Q4 		$278K Buy
7,081
+4,904
+225% +$148K ﹤0.01% 3036
2019
Q3 		$53K Sell
2,177
-6,055
-74% -$184K ﹤0.01% 3895
2019
Q2 		$289K Sell
8,232
-21,844
-73% -$868K ﹤0.01% 3623
2019
Q1 		$1.34M Buy
30,076
+5,348
+22% +$270K ﹤0.01% 2783
2018
Q4 		$1.19M Sell
24,728
-30,683
-55% -$1.86M ﹤0.01% 2763
2018
Q3 		$3.7M Buy
55,411
+13,522
+32% +$753K ﹤0.01% 2431
2018
Q2 		$1.97M Sell
41,889
-9,768
-19% -$539K ﹤0.01% 2969
2018
Q1 		$2.92M Buy
51,657
+14,181
+38% +$767K ﹤0.01% 2626
2017
Q4 		$1.86M Buy
37,476
+26,698
+248% +$1.65M ﹤0.01% 2772
2017
Q3 		$818K Buy
10,778
+4,038
+60% +$300K ﹤0.01% 3152
2017
Q2 		$633K Buy
6,740
+5,350
+385% +$458K ﹤0.01% 3309
2017
Q1 		$109K Sell
1,390
-2,853
-67% -$227K ﹤0.01% 3874
2016
Q4 		$352K Sell
4,243
-6,686
-61% -$605K ﹤0.01% 3385
2016
Q3 		$1.22M Sell
10,929
-6,438
-37% -$711K ﹤0.01% 2697
2016
Q2 		$1.92M Buy
17,367
+16,264
+1,475% +$1.98M ﹤0.01% 2427
2016
Q1 		$115K Sell
1,103
-10,197
-90% -$787K ﹤0.01% 3936
2015
Q4 		$910K Buy
11,300
+6,073
+116% +$483K ﹤0.01% 2933
2015
Q3 		$361K Buy
5,227
+3,753
+255% +$327K ﹤0.01% 3537
2015
Q2 		$143K Buy
1,474
+656
+80% +$70.1K ﹤0.01% 4056
2015
Q1 		$79K Sell
818
-2,760
-77% -$267K ﹤0.01% 4216
2014
Q4 		$393K Buy
3,578
+1,447
+68% +$177K ﹤0.01% 3837
2014
Q3 		$251K Buy
2,131
+2,106
+8,424% +$262K ﹤0.01% 3940
2014
Q2 		$3K Sell
25
-349
-93% -$41.2K ﹤0.01% 5682
2014
Q1 		$59K Buy
374
+362
+3,017% +$52K ﹤0.01% 4471
2013
Q4 		$1K Buy
+12
New +$1.2K ﹤0.01% 5271
2013
Q3 		– Sell
-10
Closed – – 5621
2013
Q2 		$0 Buy
+10
New +$303 ﹤0.01% 5351

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Deutsche Bank's INO Position: Q2 2025 in Review

Deutsche Bank sold out of Inovio Pharmaceuticals (INO) in Q2 2025, closing a stake of 39,025 shares — an estimated $63.6K sold.

Deutsche Bank first reported a position in INO in Q2 2013 and held it in 42 quarters. The position peaked at $3.7M in Q3 2018. 103 funds tracked by Wall St. Rank hold INO as of Q2 2025.

  • Deutsche Bank reported no remaining Inovio Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Deutsche Bank sold 39,025 Inovio Pharmaceuticals shares in Q2 2025, an estimated $63.6K.
  • Deutsche Bank first reported a position in Inovio Pharmaceuticals in Q2 2013 and held it in 42 quarters.
  • Deutsche Bank's Inovio Pharmaceuticals position peaked at $3.7M in Q3 2018.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2025.

Based on Deutsche Bank's 13F filing for Q2 2025, filed 12 Aug 2025.